nanotech investing Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib ) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
nanotech investing Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
nanotech investing Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
nanotech investing Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
nanotech investing Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
nanotech investing Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
nanotech investing Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
nanotech investing Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
nanotech investing Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
nanotech investing Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Silverco Releases Positive PEA for Producing La Negra Mine Outlining a Low Capital, 8.2 Year Mine Life Generating After-Tax NPV of $329 Million
Coelacanth Energy Announces Private Placement, Grant of Stock Options and Grant of Restricted Share Units
